Zealand Pharma A/S' obesity drug pipeline, including petrelintide, shows promise but faces high risks. Click to explore ZLDPF ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight ...

The firm’s current valuation of approximately DKK 790 for Zealand Pharma represents their confidence in the company’s growth prospects, particularly with the inclusion of the Roche deal for ...

Zealand Pharma A/S, a biotechnology company, has appointed Steven Johnson as Chief Development Officer.